Drug Profile
Zoptarelin doxorubicin - AEterna Zentaris Inc
Alternative Names: AEZS-108; AN-152; D-81858; Doxorubicin-GnRH agonist conjugate; ZEN-008; Zoptarelin doxorubicin acetate; ZoptrexLatest Information Update: 13 Jul 2021
Price :
$50
*
At a glance
- Originator Tulane University
- Developer AEterna Zentaris Inc; National Cancer Institute (USA); University of Southern California
- Class Amines; Anthracyclines; Cytostatic antibiotics; Doxorubicins; Drug conjugates; Naphthacenes; Pyrans
- Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Endometrial cancer
Highest Development Phases
- Discontinued Endometrial cancer; Ovarian cancer; Prostate cancer; Triple negative breast cancer; Urogenital cancer